236 related articles for article (PubMed ID: 34092972)
1. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets.
Chen SL; Wang GP; Shi DR; Yao SH; Chen KD; Yao HP
World J Gastroenterol; 2021 May; 27(20):2507-2520. PubMed ID: 34092972
[TBL] [Abstract][Full Text] [Related]
2. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
Yao HP; Tong XM; Hudson R; Wang MH
J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
[TBL] [Abstract][Full Text] [Related]
3. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
6. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.
Kang CM; Babicky ML; Lowy AM
Pancreas; 2014 Mar; 43(2):183-9. PubMed ID: 24518495
[TBL] [Abstract][Full Text] [Related]
7. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
9. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
10. Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.
Yao HP; Suthe SR; Tong XM; Wang MH
Ther Adv Med Oncol; 2020; 12():1758835920920069. PubMed ID: 32426050
[TBL] [Abstract][Full Text] [Related]
11. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
12. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
Yao HP; Suthe SR; Hudson R; Wang MH
Drug Discov Today; 2020 Jul; 25(7):1160-1173. PubMed ID: 32479905
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
16. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
[TBL] [Abstract][Full Text] [Related]
19. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.
Kato A; Ng S; Thangasamy A; Han H; Zhou W; Raeppel S; Fallon M; Guha S; Ammanamanchi S
Mol Carcinog; 2021 Nov; 60(11):734-745. PubMed ID: 34347914
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
